Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

NCT01660971 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

19

Enrollment

NIH

Sponsor class

Conditions

Metastatic Pancreatic Adenocarcinoma
Recurrent Pancreatic Carcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7

Interventions

DRUG: Dasatinib
DRUG: Erlotinib Hydrochloride
DRUG: Gemcitabine Hydrochloride

Sponsor

National Cancer Institute (NCI)